BioCentury
ARTICLE | Company News

InterMune Life other research news

June 5, 1995 7:00 AM UTC

The Toronto company and the British National Health Service entered into a research agreement to determine the role of INLI's PP14 in the diagnosis of endometrial hyperplasia and endometrial cancers.

The work will take place at the InterMune Biomedical Research Unit at the Jessup Hospital for Women in Sheffield, U.K. The focus of the study is to determine whether the concentration of endometrial proteins, including PP14, CA125 and polypeptide tissue antigen, differs in women at different stages of reproductive life, and whether they are predictive of endometrial malignancy. ...